CA2995021A1 - Transinfected lymphocytes for anti-tumor therapy - Google Patents

Transinfected lymphocytes for anti-tumor therapy Download PDF

Info

Publication number
CA2995021A1
CA2995021A1 CA2995021A CA2995021A CA2995021A1 CA 2995021 A1 CA2995021 A1 CA 2995021A1 CA 2995021 A CA2995021 A CA 2995021A CA 2995021 A CA2995021 A CA 2995021A CA 2995021 A1 CA2995021 A1 CA 2995021A1
Authority
CA
Canada
Prior art keywords
cells
lymphocyte
cell
tumor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2995021A
Other languages
English (en)
French (fr)
Inventor
Esteban Veiga Chacon
Aranzazu CRUZ ADALIA
Guillermo Ramirez Santiago
Balbino Alarcon Sanchez
Francisco Sanchez Madrid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Autonomous University of Madrid
Hospital Universitario de la Princesa
Original Assignee
Consejo Superior de Investigaciones Científicas
Autonomous University of Madrid
Hospital Universitario de la Princesa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas, Autonomous University of Madrid, Hospital Universitario de la Princesa filed Critical Consejo Superior de Investigaciones Científicas
Publication of CA2995021A1 publication Critical patent/CA2995021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2995021A 2015-08-07 2016-08-08 Transinfected lymphocytes for anti-tumor therapy Abandoned CA2995021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201531177 2015-08-07
ESP201531177 2015-08-07
PCT/ES2016/070597 WO2017025657A1 (es) 2015-08-07 2016-08-08 Linfocitos transinfectados para terapia anti-tumoral

Publications (1)

Publication Number Publication Date
CA2995021A1 true CA2995021A1 (en) 2017-02-16

Family

ID=56936436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2995021A Abandoned CA2995021A1 (en) 2015-08-07 2016-08-08 Transinfected lymphocytes for anti-tumor therapy

Country Status (6)

Country Link
US (1) US20180228840A1 (cg-RX-API-DMAC10.html)
EP (1) EP3333255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018522594A (cg-RX-API-DMAC10.html)
AU (1) AU2016307370A1 (cg-RX-API-DMAC10.html)
CA (1) CA2995021A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017025657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12087428B2 (en) * 2020-12-29 2024-09-10 Kpn Innovations Llc Systems and methods for generating a body degradation reduction program

Also Published As

Publication number Publication date
WO2017025657A1 (es) 2017-02-16
EP3333255A1 (en) 2018-06-13
US20180228840A1 (en) 2018-08-16
AU2016307370A1 (en) 2018-03-01
JP2018522594A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
JP6207783B2 (ja) 抗原特異的ｔ細胞の増殖のための方法
Palucka et al. Dendritic cells and immunity against cancer
Van der Most et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
Fowler et al. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease
Palucka et al. Designing vaccines based on biology of human dendritic cell subsets
CN102597222B (zh) 用于增殖抗原特异性t细胞的方法
Palucka et al. Dendritic cells: a critical player in cancer therapy?
US8475785B2 (en) Allogeneic cancer cell-based immunotherapy
Florek et al. Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models
CN106456730A (zh) 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
Newman et al. Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice
Keshavarz-Fathi et al. Cancer immunology
US20180228840A1 (en) Transinfected lymphocytes for anti-tumor therapy
US20240076616A1 (en) Method for t-cell expansion and related medical applications
Veiga et al. Lymphocytes transfectes pour therapie antitumorale
Asada et al. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice
CA3030779A1 (en) Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
Prophylactic Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models
Cloak Cancer Immunoediting and Hijacking of the Immune
Jæhger Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy
Garcia et al. Cancer immunology and novel strategies for immunotherapy
Zhang Tolerogenic CD4⁻ 8⁻ Dendritic Cells and their Conversion into Immunogenic Ones via TLR9 Signaling

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210703

FZDE Discontinued

Effective date: 20240109